[{"id":"10546027-b8fd-4d19-9e12-032fc4a20162","acronym":"","url":"https://clinicaltrials.gov/study/NCT02491840","created_at":"2021-01-18T12:00:42.960Z","updated_at":"2024-07-02T16:35:40.221Z","phase":"","brief_title":"Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study","source_id_and_acronym":"NCT02491840","lead_sponsor":"University Hospital, Strasbourg, France","biomarkers":" HER-2 • FGFR2","pipe":" | ","alterations":" HER-2 expression • MET expression • FGFR2 expression • FGFR2b expression","tags":["HER-2 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • MET expression • FGFR2 expression • FGFR2b expression"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2023-08-11"},{"id":"434f2313-9f1f-4287-82bb-2e00944ce448","acronym":"","url":"https://clinicaltrials.gov/study/NCT01881217","created_at":"2021-01-18T08:26:02.192Z","updated_at":"2025-02-25T17:06:51.733Z","phase":"Phase 1","brief_title":"First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors","source_id_and_acronym":"NCT01881217","lead_sponsor":"Bayer","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 expression • FGFR2b expression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 expression • FGFR2b expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aprutumab (BAY 1179470)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 06/28/2013","start_date":" 06/28/2013","primary_txt":" Primary completion: 03/18/2016","primary_completion_date":" 03/18/2016","study_txt":" Completion: 08/16/2016","study_completion_date":" 08/16/2016","last_update_posted":"2017-09-14"}]